A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)
A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic Treatment
Sponsor: AbbVie
This PHASE2/PHASE3 trial investigates Hepatocellular Carcinoma and is currently actively recruiting participants. AbbVie leads this study, which shows 17 recorded versions since 2024 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
17 versions recorded-
Dec 2025 — Present [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE2/PHASE3
Status: Active Not Recruiting → Recruiting
-
Apr 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2/PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2025 — Apr 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2/PHASE3
▶ Show 12 earlier versions
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting · Phase: PHASE2 → PHASE2_PHASE3
-
Nov 2023 — Jan 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AbbVie
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abilene, United States , Barcelona, Spain , Bobigny, France , Bologna, Italy , Chicago, United States , Clichy, France , Córdoba, Spain , Dallas, United States , Detroit, United States , Duarte, United States and 25 more locations